Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX) from its SEC filings: 2025 revenue $1.3 million (+550% vs the year before), net margin -10774%, free cash flow -$129.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $1.3 million |
| Revenue growth | +550% |
| Net income | -$140.1 million |
| Net margin | -10773.5% |
| Free cash flow | -$129.8 million |
| Diluted EPS | $-9.04 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $133.3 million |
| Long-term debt | $176.3 million |
| Share count, 1 year | +2% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.